HomeProductsBioactive CompoundsAutophagyAutophagy ModulatorsCediranib
Chemical structure of CAS 288383-20-0

Cediranib

In Stock•Starting at $70 for 50 mg•Purity ≥ 95%
CAS No.288383-20-0
MDL No.MFCD09954115
MFC25H27FN4O3
MW450.50
InChI KeyXXJWYDDUDKYVKI-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
50 mg95%$70In Stock
100 mg95%$116In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline is an aromatic ether.

CAS No.288383-20-0
Product NameCediranib

Biological Targets

PDGFRB·PDGFRA·KIT·FLT1·FLT4·

Associated Conditions

rectum cancer·ovarian cancer·prostate cancer·cancer·neoplasm·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.

European radiology • Vol. 17, Issue 7 • 2007
PMID: 17072618DOI: 10.1007/s00330-006-0425-9

Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.

Cancer cell • Vol. 11, Issue 1 • 2007
PMID: 17222788PMC: PMC2952447DOI: 10.1016/j.ccr.2006.12.008

Anti-angiogenic and anti-HER therapy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie • Vol. 60, Issue 6 • 2006
PMID: 16815667DOI: 10.1016/j.biopha.2006.06.001

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.

Carcinogenesis • Vol. 27, Issue 10 • 2006
PMID: 16782971DOI: 10.1093/carcin/bgl113

Documentation

Similar Products